Peptides in the regulation of glucagon secretion
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Glucose homeostasis is maintained by the glucoregulatory hormones, glucagon, insulin and somatostatin, secreted from the islets of Langerhans. Glucagon is the body's most important anti-hypoglycemic hormone, mobilizing glucose from glycogen stores in the liver in response to fasting, thus maintaining plasma glucose levels within healthy limits. Glucagon secretion is regulated by both circulating nutrients, hormones and neuronal inputs. Hormones that may regulate glucagon secretion include locally produced insulin and somatostatin, but also urocortin-3, amylin and pancreatic polypeptide, and from outside the pancreas glucagon-like peptide-1 and 2, peptide tyrosine tyrosine and oxyntomodulin, glucose-dependent insulinotropic polypeptide, neurotensin and ghrelin, as well as the hypothalamic hormones arginine-vasopressin and oxytocin, and calcitonin from the thyroid. Each of these hormones have distinct effects, ranging from regulating blood glucose, to regulating appetite, stomach emptying rate and intestinal motility, which makes them interesting targets for treating metabolic diseases. Awareness regarding the potential effects of the hormones on glucagon secretion is important since secretory abnormalities could manifest as hyperglycemia or even lethal hypoglycemia. Here, we review the effects of each individual hormone on glucagon secretion, their interplay, and how treatments aimed at modulating the plasma levels of these hormones may also influence glucagon secretion and glycemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 2×
“The anorexic effects of PYY3− 36 are driven by activation of Y2 receptors on neurons in the arcuate nucleus, as demonstrated by the use of Y2R antagonists as well as Y2R knockout mice [114], [112], but the mechanism downstream from receptor activation that facilitates”
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 1×
“concentrations are significantly lower in T2D [121] and obesity [122] suggesting the PYY is not involved in the impaired insulin secretion.”
Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes
Segerstolpe, Å., Palasantza, A., Eliasson, P., Andersson, E.-M., Andréasson, A.-C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, M. K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.020 · Cited by 1,550 · cited 1×
“found [13,14,175,176], or found in very low amounts.”
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 1×
“SGLT2 is interesting in the scope of glucagon regulation as SGLT2 inhibitors are widely used in diabetes treatment, and studies have associated SGLT2 inhibitors with an increase in glucagon secretion[29],[30],[31].”
Müller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.005 · Cited by 1,034
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 1×
“SGLT2 is interesting in the scope of glucagon regulation as SGLT2 inhibitors are widely used in diabetes treatment, and studies have associated SGLT2 inhibitors with an increase in glucagon secretion[29],[30],[31].”
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“Due to the rapid degradation of GLP-1 by DPP-4, GLP-1(9–36) is the most abundant form of GLP-1 in the circulation [189], with some studies”
Self-citationBiochemical and cellular properties of insulin receptor signalling
Haeusler, R. A., McGraw, T. E., & Accili, D. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.89 · Cited by 739 · cited 1×
“factors, protein synthesis and receptor/transporter translocation[40].”
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Neuropeptide, Y, peptide YY and pancreatic polypeptide in the gut-brain axis
Holzer, P., Reichmann, F., & Farzi, A. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.08.005 · Cited by 501
Pancreatic Polypeptide Reduces Appetite and Food Intake in Humans
Batterham, R. L., Le Roux, C. W., Cohen, M. A., Park, A. J., Ellis, S. M., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030630 · Cited by 496
Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms
De, S., Wirthensohn, D. C., Flagmeier, P., Hughes, C., Aprile, F. A., Ruggeri, F. S., Whiten, D. R., Emin, D., Xia, Z., Varela, J. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09477-3 · Cited by 448
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372 · cited 1×
“albeit with lower affinity (~100-fold) than the receptors primary ligands, glucagon and GLP-1[218],[219].”
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Self-citationGlucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 1×
“insulin secretion, is the primary cause for hyperglycemia in diabetes [3].”
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · cited 2×
“treatment (completion rates: 73–77 % for Cotadutide, 81 % for placebo, 94 % for liraglutide) [232].”
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationPlasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303
Plasma Copeptin and the Risk of Diabetes Mellitus
Enhörning, S., Wang, T. J., Nilsson, P. M., Almgren, P., Hedblad, B., Berglund, G., Struck, J., Morgenthaler, N. G., Bergmann, A., Lindholm, E., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.909663 · Cited by 299 · cited 3×
“different AVP receptor sub-types; V2R in the renal collecting ducts [282], V1aR located in the liver and vasculature [283,284], V1bR in the”
Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276 · cited 1×
“Treatments with GLP-1 analogs and DPP-4 inhibitors (aimed at prolonging the half-life of released GLP-1), are both effective methods for treating T2D, both because of the glucose-dependent stimulation of insulin secretion (which means that hypoglycemia is avoided), but also because of the inhibitory actions on glucago…”
Self-citationKasichayanula, S., Liu, X., LaCreta, F., Griffen, S. C., & Boulton, D. W. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0104-3 · Cited by 276
Muff, R., Bühlmann, N., Fischer, J. A., & Born, W. (1999) · Endocrinology · doi:10.1210/endo.140.6.6930 · Cited by 273
Glucose or Insulin, but not Zinc Ions, Inhibit Glucagon Secretion From Mouse Pancreatic α-Cells
Ravier, M. A., & Rutter, G. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1789 · Cited by 264
De Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257 · cited 1×
“natural α-cell), 20 % of α-cells were reported to express the GLP-1R [177], while in another study it was expressed in only ~1% of a FACS sorted primary α-cell population [178].”
Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion
van der Meulen, T., Donaldson, C. J., Cáceres, E., Hunter, A. E., Cowing-Zitron, C., Pound, L. D., Adams, M. W., Zembrzycki, A., Grove, K. L., & Huising, M. O. (2015) · Nature Medicine · doi:10.1038/nm.3872 · Cited by 256
Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats
Deblon, N., Veyrat-Durebex, C., Bourgoin, L., Caillon, A., Bussier, A.-L., Petrosino, S., Piscitelli, F., Legros, J.-J., Geenen, V., Foti, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025565 · Cited by 254 · cited 1×
“by OT infusions in another study involving DIO mice [326].”
Moens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250
Low sympathetic tone and obese phenotype in oxytocin-deficient mice
Camerino, C. (2009) · Obesity · doi:10.1038/oby.2009.12 · Cited by 235 · cited 1×
“showed decreased insulin secretion, increased insulin resistance and impaired glucose tolerance [324,325], morbidities that were improved”
Gerich, J. E., Charles, M. A., & Grodsky, G. M. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107823 · Cited by 230 · cited 6×
“A general finding that challenges the notion of insulin as the primary regulator of glucagon secretion, is that glucagon secretion is inhibited at glucose concentrations below the threshold for glucose stimulated insulin secretion (GSIS) [14,43,44].”
InfluentialZhang, Q., Ramracheya, R., Lahmann, C., Tarasov, A., Bengtsson, M., Braha, O., Braun, M., Brereton, M., Collins, S., Galvanovskis, J., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.014 · Cited by 225
Adriaenssens, A. E., Svendsen, B., Lam, B. Y. H., Yeo, G. S. H., Holst, J. J., Reimann, F., & Gribble, F. M. (2016) · Diabetologia · doi:10.1007/s00125-016-4033-1 · Cited by 223
Self-citationGlucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells
Vieira, E., Salehi, A., & Gylfe, E. (2007) · Diabetologia · doi:10.1007/s00125-006-0511-1 · Cited by 218 · cited 6×
“A general finding that challenges the notion of insulin as the primary regulator of glucagon secretion, is that glucagon secretion is inhibited at glucose concentrations below the threshold for glucose stimulated insulin secretion (GSIS) [14,43,44].”
InfluentialPeptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity
Boey, D., Lin, S., Karl, T., Baldock, P., Lee, N., Enriquez, R., Couzens, M., Slack, K., Dallmann, R., Sainsbury, A., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0237-0 · Cited by 186
Heller, R. S., Kieffer, T. J., & Habener, J. F. (1997) · Diabetes · doi:10.2337/diab.46.5.785 · Cited by 179
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1806 · Cited by 163 · cited 1×
“Unfortunately, frequent adverse effects are associated with PYY3− 36 administration (nausea and vomiting) [130], and difficulties in generating analogs of PYY1− 36 that are resistant to DPP-4 degradation, without losing efficacy of β-cell survival and growth [128] makes this ambition challenging.”
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162 · cited 1×
“The goal of most treatments is to lower glucose via increases in insulin secretion, but many of these drugs are also potential regulators of glucagon secretion [10].”
Plasma Vasopressin in Uncontrolled Diabetes Mellitus
Zerbe, R. L., Vinicor, F., & Robertson, G. L. (1979) · Diabetes · doi:10.2337/diab.28.5.503 · Cited by 158
PEDERSON, R. A., & BROWN, J. C. (1978) · Endocrinology · doi:10.1210/endo-103-2-610 · Cited by 156
Olsen, H. L., Theander, S., Bokvist, K., Buschard, K., Wollheim, C. B., & Gromada, J. (2005) · Endocrinology · doi:10.1210/en.2005-0800 · Cited by 156
δ‐cells and β‐cells are electrically coupled and regulate α‐cell activity via somatostatin
Briant, L. J. B., Reinbothe, T. M., Spiliotis, I., Miranda, C., Rodriguez, B., & Rorsman, P. (2018) · The Journal of Physiology · doi:10.1113/jp274581 · Cited by 155
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
Vergari, E., Knudsen, J. G., Ramracheya, R., Salehi, A., Zhang, Q., Adam, J., Asterholm, I. W., Benrick, A., Briant, L. J. B., Chibalina, M. V., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08193-8 · Cited by 152 · cited 5×
“concentrations up to 10 μmol/L [14,23], perhaps owing to the already very high interstitial insulin concentrations surrounding the α- cells.”
InfluentialStimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver
Hems, D. A., & Whitton, P. D. (1973) · Biochemical Journal · doi:10.1042/bj1360705 · Cited by 150 · cited 1×
“These effects were attenuated by prior administration of a V1aR specific antagonist, whereas V1bR antagonists had no effect, suggesting that the AVP driven hyperglycemia primarily stems from gluconeogenic effects on the liver[300],[301],[302] (that expresses V1aR).”
Jensen, C. B., Pyke, C., Rasch, M. G., Dahl, A. B., Knudsen, L. B., & Secher, A. (2018) · Endocrinology · doi:10.1210/en.2017-00812 · Cited by 145 · cited 1×
“have been generated, providing a clearer picture [181].”
Nauck, M., Frid, A., Hermansen, K., Thomsen, A. B., During, M., Shah, N., Tankova, T., Mitha, I., & Matthews, D. R. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12012 · Cited by 144
Ghrelin Directly Stimulates Glucagon Secretion from Pancreatic α-Cells
Chuang, J.-C., Sakata, I., Kohno, D., Perello, M., Osborne-Lawrence, S., Repa, J. J., & Zigman, J. M. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1001 · Cited by 141 · cited 10×
“was abolished in mice lacking the GHSR [263].”
InfluentialThe oxytocin receptor antagonist atosiban inhibits cell growth via a “biased agonist” mechanism
Reversi, A., Rimoldi, V., Marrocco, T., Cassoni, P., Bussolati, G., Parenti, M., & Chini, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409945200 · Cited by 139 · cited 1×
“This is not unlikely, as a similar mode of action was shown for atisoban [331], a clinically used OXTR antagonist.”
Winther-Sørensen, M., Galsgaard, K. D., Santos, A., Trammell, S. A. J., Sulek, K., Kuhre, R. E., Pedersen, J., Andersen, D. B., Hassing, A. S., Dall, M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101080 · Cited by 135
Self-citationRamracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13852 · Cited by 128 · cited 2×
“Several studies have shown expression of the GLP-1R on somatostatin secreting δ cells [179,180,183], and the finding that in isolated α-cells, GLP-1 paradoxically stimulated glucagon secretion (in stark contrast to in vivo studies where GLP-1 inhibits glucagon secretion),”
Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions
Whitton, P. D., Rodrigues, L. M., & Hems, D. A. (1978) · Biochemical Journal · doi:10.1042/bj1760893 · Cited by 123
Gromada, J., Høy, M., Buschard, K., Salehi, A., & Rorsman, P. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.00519.x · Cited by 120 · cited 1×
“The somatostatin receptors are G-protein coupled receptors (GPCR), coupled to Gi/o proteins that inhibit adenylyl cyclase (AC) and cyclic adenosine monophosphate (cAMP) production and prevent cell depolarization and secretion by reducing the activity of voltage-gated calcium channels [52,56,57].”
Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
Wewer Albrechtsen, N. J., Færch, K., Jensen, T. M., Witte, D. R., Pedersen, J., Mahendran, Y., Jonsson, A. E., Galsgaard, K. D., Winther-Sørensen, M., Torekov, S. S., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4535-5 · Cited by 119 · cited 1×
“amino acids by stimulating ureagenesis in the liver [36,37].”
Self-citationHurley, D. L., Tiegs, R. D., Wahner, H. W., & Heath, H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708273170904 · Cited by 118 · cited 1×
“display normal plasma calcium levels, with no apparent difference in bone structure [140,141].”
Role of oxytocin signaling in the regulation of body weight
Blevins, J. E., & Ho, J. M. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9260-x · Cited by 108 · cited 1×
“down-stream effector of leptin signaling, be a possible treatment for obesity in leptin resistant individuals [320].”
Intra-islet insulin permits glucose to directly suppress pancreatic A cell function.
Greenbaum, C. J., Havel, P. J., Taborsky, G. J., & Klaff, L. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115375 · Cited by 106
Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes · doi:10.2337/db18-0317 · Cited by 104 · cited 1×
“Only few studies find appreciable expression of GLP-1R on α-cells [174], and most often it is either not”
Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2005 · Cited by 104 · cited 1×
“secretion [193], and so its effects on islet secretion are negligible.”
Self-citationCalcitonin: Physiology or fantasy?
Davey, R. A., & Findlay, D. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1869 · Cited by 101 · cited 2×
“In humans, CT primarily reduces plasma calcium by directly inhibiting osteoclast activity, but also by reducing calcium reabsorption in the kidneys[140].”
Valdecantos, M. P., Pardo, V., Ruiz, L., Castro‐Sánchez, L., Lanzón, B., Fernández‐Millán, E., García‐Monzón, C., Arroba, A. I., González‐Rodríguez, Á., Escrivá, F., et al. (2017) · Hepatology · doi:10.1002/hep.28962 · Cited by 100 · cited 14×
“In addition to its pancreatic effects, OXM may also activate GCGR on hepatocytes, stimulating glucose production, but this is counteracted by OXM’s ability to also stimulate insulin secretion [222,223].”
InfluentialEmerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96 · cited 1×
“promising dual-agonists are currently in phase 1 or 2 trials [231] and are being tested for their ability to activate both receptors at a ratio that ensures the benefical effects associated with dual receptor activation, while limiting adverse effects.”
Prolonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias
Andreassen, K. V., Hjuler, S. T., Furness, S. G., Sexton, P. M., Christopoulos, A., Nosjean, O., Karsdal, M. A., & Henriksen, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092042 · Cited by 89
Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88
Self-citationOxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86 · cited 3×
“healthy people is probably negligible [216].”
Self-citationGlucose controls glucagon secretion by directly modulating cAMP in alpha cells
Yu, Q., Shuai, H., Ahooghalandari, P., Gylfe, E., & Tengholm, A. (2019) · Diabetologia · doi:10.1007/s00125-019-4857-6 · Cited by 84
Abu-Basha, E. A., Yibchok-anun, S., & Hsu, W. H. (2002) · Metabolism · doi:10.1053/meta.2002.34052 · Cited by 80
Vasopressin in Rats With Genetic and Streptozocin-Induced Diabetes
Brooks, D. P., Nutting, D. F., Crofton, J. T., & Share, L. (1989) · Diabetes · doi:10.2337/diab.38.1.54 · Cited by 69
Karimian, N., Qin, T., Liang, T., Osundiji, M., Huang, Y., Teich, T., Riddell, M. C., Cattral, M. S., Coy, D. H., Vranic, M., et al. (2013) · Diabetes · doi:10.2337/db13-0164 · Cited by 66 · cited 1×
“rat models of T1D, SSTR2 antagonists corrected the well-known loss of glucagon response to hypoglycemia [77,78].”
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Self-citationSchiavon, M., Visentin, R., Göbel, B., Riz, M., Cobelli, C., Klabunde, T., & Dalla Man, C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14394 · Cited by 49
Eriksson, O., Haack, T., Hijazi, Y., Teichert, L., Tavernier, V., Laitinen, I., Berglund, J. E., Antoni, G., Velikyan, I., Johansson, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73815-5 · Cited by 46
Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00678-2 · Cited by 33
Yi, S. S., Hwang, I. K., Kim, Y. N., Kim, I. Y., Pak, S.-I., Lee, I. S., Seong, J. K., & Yoon, Y. S. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9519-2 · Cited by 30 · cited 1×
“increased in both rodent models [288,289] and humans [290,291].”
Cited by
100 years of glucagon and 100 more
Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05947-y · Cited by 117
Self-citationGlucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“OXM can naturally activate both GCGR and GLP-1R with lower potency than their primary ligands [87].”
Background
Metadata
- Authors
- Andersen, D. B., & Holst, J. J.
- Venue
- Peptides
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 148
- Pages
- 170683
- ISSN
- 0196-9781 (ISSN-L)
- OpenAlex
- W3213913294
- Cited by
- 43
- References
- 79
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.